asthma: A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors resulting in recurring periods of wheezing (a whistling sound while breathing), chest tightness, shortness of breath, mucus production and coughing. The symptoms appear due to a variety of triggers such as allergens, irritants, respiratory infections, weather changes, exercise, stress, reflux disease, medications, foods and emotional anxiety.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
196 |
4. Check minimum number of eventsNone |
196 |
5. Include endpointsNone |
196 |
6. Filter based on genotype QC (FinnGen only) |
187 |
Control definitions (FinnGen only)
- Control exclude
- IBD_BACT_INTEST_INFECTIONS
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- A04
- Name in latin
- Enteritis a Yersinia enterocolitica
Similar endpoints
↥List of similar endpoints to
Enteritis due to Yersinia enterocolitica
based on the number of shared cases.
Similar with more cases:
- Bacterial intestinal infections, IBD co-morbidities
- Infections, IBD-co-morbidities
- Intestinal infectious diseases
- Intestinal infectious diseases
- Certain infectious and parasitic diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1504 | 800 | 693 |
| Only index persons | 1361 | 727 | 634 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 40.57 | 43.10 | 37.23 |
| Only index persons | 39.86 | 42.41 | 36.93 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 187 | 106 | 81 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | 45.59 | 41.87 | 50.46 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 196
- Matched controls
- 1960
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
A04.6
ICD-10 Finland
Enteritis due to Yersinia enterocolitica
+∞
177.0
142
*
M03.2*A04.6
ICD-10 Finland
Postinfectious arthropathy in enteritis due to Yersinia enterocolitica
+∞
64.1
58
*
A07EC01
ATC
sulfasalazine; oral, rectal
9.5
37.1
51
70
J01MA02
ATC
ciprofloxacin; systemic
4.9
26.7
118
466
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
5.9
25.5
56
124
M13.9
ICD-10 Finland
Arthritis, unspecified
5.4
15.6
34
73
L01BA01
ATC
methotrexate; systemic
15.7
15.5
25
18
UJF32
NOMESCO Finland
Coloscopy
3.6
14.9
68
255
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
80.9
13.8
15
*
P01BA02
ATC
hydroxychloroquine; oral
4.7
13.4
34
83
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
3.3
12.8
62
239
M02.9
ICD-10 Finland
Reactive arthropathy, unspecified
34.6
12.8
16
5
L04AX03
ATC
methotrexate; systemic
4.2
12.2
36
99
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
5.0
12.1
28
63
H02AB06
ATC
prednisolone; systemic
2.9
11.7
114
642
M03.2
ICD-10 Finland
Other postinfectious arthropathies in diseases classified elsewhere
+∞
11.6
11
*
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.8
10.9
93
484
A02BC02
ATC
pantoprazole; systemic
3.0
10.6
143
934
0084D
ICD-9 Finland
Intestinal infections due to other organisms, Other specified bacteria[ENTERITIS YERSINIA PSEUDOTUBERCULOSA]
+∞
10.5
10
*
M02.1
ICD-10 Finland
Postdysenteric arthropathy
+∞
10.5
10
*
R50.9
ICD-10 Finland
Fever, unspecified
3.3
10.2
44
156
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.7
10.1
77
375
K52.9
ICD-10 Finland
Noninfective gastroenteritis and colitis, unspecified
8.3
9.7
21
28
H02AB07
ATC
prednisone; oral
3.4
9.5
38
128
ZX120
NOMESCO Finland
Intravenous
3.8
9.5
32
96
M46.9
ICD-10 Finland
Inflammatory spondylopathy, unspecified
31.8
9.5
12
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
4.6
9.5
24
58
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
8.5
63
300
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.4
8.4
34
115
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
4.4
8.3
22
55
A07EC02
ATC
mesalazine; oral, rectal
4.4
7.7
20
49
M45
ICD-10 Finland
Ankylosing spondylitis
8.4
7.3
15
19
J01MA12
ATC
levofloxacin; systemic
2.8
7.1
41
170
208
Kela drug reimbursment
Ulcerative colitis and Crohn's disease
4.7
7.1
17
39
K59.1
ICD-10 Finland
Functional diarrhoea
4.3
7.1
19
48
A02BC05
ATC
esomeprazole; systemic
2.3
7.0
85
497
UJF30
NOMESCO Finland
Ileoscopy through colon
3.4
6.9
27
89
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
3.7
6.8
22
64
L04AB01
ATC
etanercept; parenteral
23.5
6.7
9
*
L04AX01
ATC
azathioprine; systemic
6.1
6.6
17
30
C03CA01
ATC
furosemide; systemic
2.3
6.3
57
292
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.2
6.3
26
89
M01AX17
ATC
nimesulide; oral
2.4
6.2
49
237
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
4.1
6.1
17
44
J45.9
ICD-10 Finland
Asthma, unspecified
2.5
6.0
43
198
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
44
96
5.62
20.08
2.8
1.4
—
—
—
0
0
24
37
7.25
15.30
1.9
1.5
—
—
—
0
0
24
40
6.70
14.23
1.5
1.2
—
—
—
0
0
56
205
3.42
12.53
3.8
2.1
229.35
131.06
ug/g
1.07
51
162
156
1144
2.78
7.96
7.2
3.6
15.11
9.96
mm/h
3.27
149
1055
66
340
2.42
7.37
2.9
1.9
3.01
3.09
mg/l
0.11
58
293
127
896
2.19
6.30
15.3
9.6
4.16
4.09
e9/l
0.11
119
794
18
48
4.03
6.24
1.3
1.4
0.28
0.09
iu/ml
—
5
8
19
53
3.86
6.21
1.4
1.1
—
—
—
0
0
19
53
3.86
6.21
1.4
1.1
—
—
—
0
0
101
668
2.06
5.77
3.3
2.6
125.90
99.41
ug/l
0.37
95
625
110
756
2.04
5.59
6.4
4.9
0.00
0.00
estimate
-0.00
18
139
109
752
2.01
5.42
5.0
3.5
0.00
0.00
estimate
-0.00
19
145
65
375
2.10
5.28
1.3
1.3
0.78
0.82
u/ml
0.13
22
97
18
55
3.50
5.17
9.9
4.5
24.79
24.14
mmol/l
0.53
18
55
93
617
1.97
5.08
14.3
11.3
1.23
1.22
inr
0.05
36
179
109
766
1.95
5.00
5.0
3.6
0.00
0.00
estimate
-0.00
17
131
18
59
3.26
4.65
1.8
1.5
—
—
—
0
0
181
1564
3.06
4.52
23.6
11.7
24.69
21.46
mg/l
0.66
149
1210
22
85
2.79
4.31
1.0
1.0
—
—
—
0
0
21
80
2.82
4.22
6.4
2.7
1.58
1.39
mmol/l
0.10
14
60
78
512
1.87
4.22
3.9
3.7
35.47
38.85
ng/l
0.09
51
333
11
23
5.00
3.93
1.4
1.7
—
—
—
0
0
11
23
5.00
3.93
1.4
1.7
—
—
—
0
0
77
513
1.83
3.91
4.4
2.8
—
—
—
0
0
11
24
4.79
3.80
1.4
1.6
—
—
—
0
0
11
24
4.79
3.80
1.4
1.6
—
—
—
0
0
11
24
4.79
3.80
1.4
1.6
—
—
—
0
0
11
24
4.79
3.80
1.4
1.6
—
—
—
0
0
45
256
1.98
3.67
1.1
1.3
2.50
12.78
u/ml
1.87
21
101
14
46
3.20
3.61
1.7
2.1
—
—
—
0
0
114
867
1.75
3.60
4.7
4.4
6.33
6.65
mmol/l
0.97
109
783
11
27
4.25
3.45
1.8
2.1
22.44
23.74
mmol/l
0.59
11
27
52
317
1.87
3.45
1.7
1.5
19.75
21.98
nmol/l
0.65
47
273
23
103
2.40
3.38
1.4
1.3
—
—
—
0
0
14
48
3.06
3.37
1.2
1.3
—
—
—
0
0
6
7
8.79
3.28
1.3
1.7
—
—
—
0
0
6
7
8.79
3.28
1.3
1.7
—
—
—
0
0
84
598
1.71
3.27
4.9
3.5
—
—
—
0
0
38
213
1.97
3.22
2.4
1.8
—
—
—
0
0
25
119
2.26
3.21
8.2
4.4
5.90
5.65
kpa
0.75
25
119
12
36
3.48
3.08
2.3
2.5
—
—
—
0
0
14
52
2.82
2.96
2.8
2.4
—
—
—
0
0
10
27
3.84
2.92
1.3
1.3
—
—
—
0
0
38
221
1.89
2.89
4.8
2.6
5.02
3.65
e6/l
0.22
29
114
12
40
3.13
2.75
1.8
1.5
146.50
302.32
ug/g
—
6
25
6
10
6.15
2.72
2.3
3.7
—
—
—
0
0
165
1450
1.87
2.65
19.0
10.8
85.68
86.57
ml/min/173m2
0.17
136
1169
5
7
7.29
2.56
1.4
1.7
—
—
—
0
0
5
7
7.29
2.56
1.4
1.7
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
7
7.29
2.56
1.4
1.3
—
—
—
0
0
59
406
1.65
2.51
4.6
3.6
0.00
0.00
estimate
-0.00
18
132
8
21
3.92
2.49
1.4
1.1
—
—
—
0
0
38
234
1.77
2.40
4.1
2.5
0.84
0.85
e6/l
0.01
29
127
10
33
3.14
2.39
1.4
1.8
—
—
—
0
0
10
33
3.14
2.39
7.8
2.2
8.35
8.50
kpa
—
10
33
5
8
6.38
2.38
1.0
1.1
—
—
—
0
0
7
18
3.99
2.27
2.0
1.7
—
—
—
0
0
8
24
3.43
2.20
2.0
1.7
—
—
—
0
0
10
36
2.87
2.17
1.6
1.8
469.30
443.58
mg/l
—
10
36
57
402
1.59
2.16
4.1
2.6
0.12
0.33
e6/l
1.72
48
297
41
266
1.68
2.16
4.7
3.1
84.45
172.34
ng/l
0.43
28
181
12
49
2.54
2.15
2.9
2.2
—
—
—
0
0
64
466
1.55
2.11
2.6
3.0
2.38
2.35
mmol/l
1.51
58
418
5
10
5.10
2.08
2.4
3.6
17.60
12.00
%
—
5
10
7
20
3.59
2.07
1.4
1.7
—
—
—
0
0
17
84
2.12
2.02
1.3
1.2
28.47
451.00
u/ml
0.88
17
77
71
535
1.51
1.99
2.2
1.8
92.08
97.28
pmol/l
0.38
38
254
7
21
3.42
1.98
2.1
1.7
—
—
—
0
0
34
217
1.69
1.90
1.6
1.7
993.27
1266.56
nmol/l
1.18
28
171
41
276
1.61
1.87
1.8
2.2
—
—
—
0
0
5
12
4.24
1.83
1.2
1.2
—
—
—
0
0
48
338
1.56
1.81
3.8
3.4
656.37
1215.40
ng/l
1.24
43
283
11
47
2.42
1.81
1.5
2.1
—
—
—
0
0
6
18
3.40
1.76
1.3
1.3
—
—
—
0
0
6
18
3.40
1.76
1.0
1.2
—
—
—
0
0
8
30
2.74
1.74
1.1
1.6
—
—
—
0
0
8
30
2.74
1.74
1.4
1.4
—
—
—
0
0
7
24
2.99
1.74
1.1
1.3
—
—
—
0
0
7
24
2.99
1.74
1.4
1.4
—
—
—
0
0
7
24
2.99
1.74
1.1
1.3
—
—
—
0
0
5
13
3.92
1.72
2.2
1.5
—
—
—
0
0
5
13
3.92
1.72
1.2
1.2
—
—
—
0
0
22
128
1.81
1.69
1.9
1.7
—
—
—
0
0
6
19
3.22
1.67
2.0
1.3
—
—
—
0
0
11
50
2.27
1.60
1.0
1.1
—
—
—
0
0
38
261
1.57
1.60
1.6
2.0
—
—
—
0
0
6
22
2.78
1.44
1.2
1.7
—
—
—
0
0
33
225
1.56
1.43
2.5
2.5
2.44
2.45
mmol/l
0.11
28
200
38
268
1.52
1.42
1.3
1.3
26.53
35.00
iu/ml
0.23
12
87
12
60
2.07
1.41
1.4
1.3
—
—
—
0
0
18
105
1.79
1.38
9.9
3.7
4.16
4.67
kpa
1.00
18
105
6
26
2.35
1.19
2.5
2.9
55.00
55.81
%
—
6
26
11
57
1.99
1.19
1.3
2.1
37.27
45.32
u/l
1.13
11
51
46
350
1.41
1.18
2.5
2.0
—
—
—
0
0
23
151
1.59
1.18
2.8
1.6
—
—
—
0
0
24
160
1.57
1.16
2.0
1.8
—
—
—
0
0
5
20
2.54
1.16
1.2
1.1
—
—
—
0
0
7
30
2.38
1.13
1.4
1.3
—
—
—
0
0
21
137
1.60
1.11
2.9
2.2
399.95
394.62
nmol/l
0.04
21
124
7
33
2.16
1.06
1.0
1.1
—
—
—
0
0
5
22
2.30
1.04
3.8
1.6
3.48
7.04
u/ml
—
5
22
128
1154
1.31
1.02
3.7
3.4
—
—
—
0
0
21
146
1.49
0.87
2.9
1.5
—
—
—
0
0
84
732
1.26
0.82
3.4
2.3
—
—
—
0
0
13
83
1.61
0.77
5.4
7.4
24.39
24.20
mmol/l
0.05
13
78
129
1187
1.25
0.76
4.2
3.9
14.55
14.71
pmol/l
0.32
124
1087
9
54
1.70
0.75
1.3
1.6
—
—
—
0
0
12
180
0.64
0.72
3.5
4.0
26.33
31.25
%
—
6
122
5
26
1.95
0.71
2.4
1.9
—
—
—
0
0
5
26
1.95
0.71
2.4
1.9
—
—
—
0
0
7
41
1.73
0.70
1.9
1.6
—
—
—
0
0
12
77
1.59
0.70
1.6
1.2
—
—
—
0
0
41
335
1.28
0.67
1.9
1.9
0.82
1.12
mg/l
0.68
35
259
5
29
1.74
0.64
1.2
1.3
—
—
—
0
0
5
29
1.74
0.64
1.8
1.1
—
—
—
0
0
184
1785
1.50
0.64
31.5
17.8
39.05
40.62
%
2.69
178
1686
11
71
1.58
0.63
2.0
1.5
—
—
—
0
0
163
1555
1.29
0.62
4.7
4.4
2.82
2.81
mmol/l
0.06
156
1436
161
1534
1.28
0.62
4.1
4.0
4.73
4.70
mmol/l
0.18
153
1429
5
30
1.68
0.62
1.2
2.3
—
—
—
0
0
160
1524
1.27
0.61
4.1
4.0
1.46
1.46
mmol/l
0.03
152
1412
0
21
0.00
0.60
0.0
1.9
—
7.69
—
0
21
8
53
1.53
0.59
2.6
2.9
24.38
2686.57
u/ml
—
8
47
46
390
1.23
0.56
4.7
3.6
22.09
14.52
mg/mmol
0.27
37
243
184
1790
1.46
0.56
32.3
17.7
132.30
136.89
g/l
4.11
184
1761
6
39
1.56
0.53
1.5
1.2
—
—
—
0
0
17
224
0.74
0.53
2.1
1.8
1.24
1.41
%
0.82
17
200
12
83
1.47
0.53
4.8
6.2
25.13
25.25
mmol/l
0.04
12
83
12
83
1.47
0.53
6.2
2.1
120.75
141.62
ng/l
0.20
12
71
155
1479
1.23
0.53
4.3
4.1
5.65
5.83
mmol/l
1.29
144
1359
11
75
1.49
0.52
1.1
1.4
236.19
287.25
miu/ml
—
6
41
10
67
1.52
0.50
9.6
3.9
25.60
24.42
mmol/l
—
10
67
46
396
1.21
0.49
2.5
2.0
181.96
360.11
u/l
0.50
46
380
5
32
1.58
0.42
1.2
1.6
—
—
—
0
0
14
105
1.36
0.42
1.9
2.8
70.00
73.66
ml/min/173m2
—
8
44
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
9
66
1.38
0.39
17.4
3.6
48.67
52.62
%
—
9
66
21
171
1.26
0.37
1.6
1.6
—
—
—
0
0
9
71
1.28
0.36
2.1
2.9
0.94
1.31
%
—
9
71
6
41
1.48
0.36
2.0
1.7
—
—
—
0
0
33
285
1.19
0.35
1.6
1.5
—
—
—
0
0
38
333
1.18
0.34
4.1
4.1
25.49
22.54
%
0.51
13
140
10
78
1.30
0.24
1.3
2.8
65.32
62.10
u/ml
—
10
78
16
134
1.21
0.23
1.1
1.2
66.74
197.60
iu/ml
—
5
45
115
1112
1.08
0.18
4.3
2.7
45.67
45.16
u/l
0.03
107
1066
5
67
0.74
0.17
1.4
1.5
—
—
—
0
0
8
70
1.15
0.16
1.8
1.8
—
—
—
0
0
15
130
1.17
0.16
3.1
3.2
—
—
—
0
0
6
79
0.75
0.16
1.3
1.5
586.33
302.38
mu/l
—
6
71
9
78
1.16
0.15
1.4
1.8
—
—
—
0
0
12
138
0.86
0.13
1.7
1.5
—
—
—
0
0
18
161
1.13
0.13
7.8
7.9
—
—
—
0
0
147
1444
1.07
0.12
5.2
4.5
1.76
1.87
mu/l
0.78
139
1327
17
153
1.12
0.11
4.6
7.6
2.13
1.03
mmol/l
1.40
12
118
6
56
1.07
0.08
1.5
1.6
—
—
—
0
0
26
244
1.08
0.08
2.5
2.7
0.78
0.69
ug/l
0.15
14
138
7
81
0.86
0.07
1.9
1.6
—
—
—
0
0
37
356
1.05
0.06
1.5
1.6
—
—
—
0
0
141
1396
1.04
0.05
6.4
5.1
38.76
39.04
mmol/mol
0.13
135
1312
149
1477
1.04
0.04
3.9
3.6
1.29
1.30
mmol/l
0.03
140
1360
16
153
1.05
0.01
4.8
7.5
5.03
5.08
kpa
0.06
16
146
16
153
1.05
0.01
4.8
7.4
10.96
12.44
kpa
1.18
16
147
17
167
1.02
0.00
7.1
6.5
104.47
104.03
mmol/l
0.15
17
167
11
108
1.02
0.00
5.4
3.6
1.24
1.23
mmol/l
0.58
11
99
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
7
76
0.92
0.00
1.7
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
7
77
0.91
-0.00
1.7
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
13.50
—
0
6
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.7
—
—
—
0
0
7
77
0.91
-0.00
1.7
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
8.94
—
0
9
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint YERSINIAENTERITIS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| YERSINIAENTERITIS | 1.696 [1.28, 2.24] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.191 |
During the follow-up period (1.1.1998 — 31.12.2019), 105 out of 626 females with YERSINIAENTERITIS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| YERSINIAENTERITIS | 1.525 [1.11, 2.1] | 0.01 |
| Birth year | 0.988 [0.98, 1.0] | 0.011 |
During the follow-up period (1.1.1998 — 31.12.2019), 71 out of 526 males with YERSINIAENTERITIS died.
Mortality risk
Mortality risk for people of age
years, who have YERSINIAENTERITIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.154% | 0.26% |
| 5 | 1.027% | 1.703% |
| 10 | 2.513% | 4.274% |
| 15 | 4.725% | 8.398% |
| 20 | 8.16% | 14.254% |
Relationships between endpoints
↥Index endpoint: YERSINIAENTERITIS – Enteritis due to Yersinia enterocolitica
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data